巨噬细胞来源马达蛋白KIF13B通过MERTK促进胞葬作用并预防小鼠动脉粥样硬化
本研究在人类队列和小鼠模型中探究KIF13B在动脉粥样硬化中的作用。发现KIF13B表达在动脉粥样硬化患者中降低,髓系Kif13b缺失加重斑块但不改变血脂,机制涉及KIF13B/ITCH/CBL/MERTK轴调控巨噬细胞胞葬作用,CBL拮抗剂NX-1607可逆转上述缺陷并减轻动脉粥样硬化。
要点
- KIF13B表达在动脉粥样硬化患者中显著降低,且与小鼠病变严重程度负相关。
- 髓系Kif13b缺失不改变血脂但加重斑块、增加巨噬细胞浸润和凋亡细胞。
- NX-1607(CBL拮抗剂)可恢复MERTK水平、改善胞葬作用并减轻病变。
核心结论
- KIF13B通过KIF13B/ITCH/CBL/MERTK轴维持巨噬细胞胞葬作用,从而预防动脉粥样硬化发展。
- KIF13B可能是未来临床试验中治疗动脉粥样硬化的潜在治疗靶点。
研究设计与样本
- 研究评估了人类队列数据和患者颈动脉斑块中KIF13B表达与动脉粥样硬化进展的关系。
- 构建了Kif13b-/-;Ldlr-/-双敲除小鼠和髓系特异性Kif13b敲除小鼠(Lyz2 Cre;Kif13bf/f),并采用AAV8介导的PCSK9过表达。
- Ldlr-/-小鼠接受来自Kif13b-/-;Ldlr-/-或Ldlr-/-小鼠的骨髓移植,并喂食西方饮食12周。
主要发现
- KIF13B表达在动脉粥样硬化患者中显著降低,且在WD喂养的Ldlr-/-小鼠中与动脉粥样硬化进展严重程度负相关。
- 与相应对照小鼠相比,Kif13b-/-;Ldlr-/-小鼠血浆总胆固醇显著升高且动脉粥样硬化病变更严重。
- 髓系Kif13b缺失和骨髓移植缺乏Kif13b的巨噬细胞均不改变血浆脂质水平,但导致更大的动脉粥样硬化斑块伴巨噬细胞浸润增加和更多凋亡细胞。
- 体外实验显示,氧化低密度脂蛋白处理下,Kif13b缺陷巨噬细胞胆固醇积累显著增加且胞葬作用受损,伴MERTK表达降低。
- 机制研究揭示Kif13b缺失降低ITCH表达,导致CBL介导的MERTK泛素化降解加速;口服CBL拮抗剂NX-1607可显著逆转MERTK蛋白水平降低和胞葬作用缺陷,最终保护免受Kif13b缺失引起的动脉粥样硬化发展。
临床怎么用
- KIF13B/ITCH/CBL/MERTK轴可能成为动脉粥样硬化治疗的新靶点。
- CBL拮抗剂NX-1607在动物模型中显示出恢复胞葬作用和减轻动脉粥样硬化的潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Atherosclerosis is a chronic inflammatory disorder with high morbidity and mortality rates worldwide. Emerging evidence has reported that kinesin family member 13B (KIF13B), a crucial motor protein, integrates hepatic lipid metabolism and inflammatory response to protect liver disease. However, the relationship between KIF13B and atherosclerosis remains unknown. The present study aimed to elucidate the specific role of KIF13B in atherosclerosis and its potential therapeutic significance. METHODS: The investigation first assessed the relationship between the expression levels of KIF13B and the progression of atherosclerosis in human cohort data and carotid plaques from patients. Subsequently, the authors generated Kif13b knockout (Kif13b-/-) mice on low-density lipoprotein receptor (Ldlr)-deficient background (Ldlr-/-) to obtain double knockouts (Kif13b-/-;Ldlr-/-) and myeloid-specific Kif13b knockout mice (Lyz2 Cre;Kif13bf/f) with adeno-associated virus 8 (AAV8)-mediated overexpression of proprotein convertase subtilisin/kexin type 9 (PCSK9). Moreover, Ldlr-/- mice received bone marrow transplants from either Kif13b-/-;Ldlr-/- or Ldlr-/- mice and were fed a Western diet (WD) for 12 weeks. RESULTS: KIF13B expression was significantly reduced in patients with atherosclerosis and negatively associated with the severity of atherosclerotic progress in WD-fed Ldlr-/- mice. In contrast to Kif13b-/-;Ldlr-/- mice showing a significant increase in plasma total cholesterol and more atherosclerosis lesions compared with the corresponding control mice, depletion of myeloid-derived Kif13b and bone marrow transplantation with macrophages lacking Kif13b both did not alter plasma lipid levels but elicited the larger atherosclerotic plaques with increased macrophage infiltration and more apoptotic cells. In vitro studies showed that upon oxidized low-density lipoprotein treatment, macrophages with Kif13b deficiency also display significantly increased cholesterol accumulation and impaired efferocytosis with reduced MER proto-oncogene, tyrosine kinase (MERTK) expression. Mechanistic study revealed that loss of Kif13b decreased the expression of Itchy E3 ubiquitin protein ligase (ITCH), leading to accelerated ubiquitination and degradation of MERTK mediated by Casitas B-lineage lymphoma (CBL) in macrophages. Moreover, oral administration of NX-1607, a CBL antagonist, significantly reversed the reduction of MERTK protein level and defective efferocytosis, ultimately protecting against atherosclerotic development caused by Kif13b deficiency in vivo. CONCLUSIONS: The study results revealed that KIF13B is a crucial modulator responsible for maintaining proper macrophage efferocytosis to prevent atherosclerotic development through KIF13B/ITCH/CBL/MERTK axis, suggesting that KIF13B will be a potential therapeutic target for the treatment of atherosclerosis in future clinical trials.
引用
- Xu Y, Chen J, Liu Y, et al. The macrophage-derived motor protein KIF13B enhances MERTK-mediated efferocytosis and prevents atherosclerosis in mice. Eur Heart J. 2025. PMID: 40709729. doi:10.1093/eurheartj/ehaf523
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。